Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company released its 2Q2024 earnings and highlighted advances made with its signature treatment-Lomecel-B.</li><li> The treatment has made significant progress and received multiple FDA designation for both Alzheimer's Disease and the devastating HLHS.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company released its 2Q2024 earnings and highlighted advances made with its signature treatment-Lomecel-B. The treatment has made significant progress and received multiple FDA designation for both Alzheimer's Disease and the devastating HLHS.

LGVN: Financial Update Highlights Successes